title: Response to Campbell, Spackman, Sullivan letter to Allergy.
authors.forename: R
authors.initials: R
authors.lastname: Brown
authors.forename: F
authors.initials: F
authors.lastname: Turk
authors.forename: P
authors.initials: P
authors.lastname: Dale
authors.forename: J
authors.initials: J
authors.lastname: Bousquet
mesh_terms: D018927:Anti-Asthmatic Agents / Q000191:economics* / Q000627:therapeutic use; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000188:drug therapy* / Q000191:economics / Q000401:mortality; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D006801:Humans; D000069444:Omalizumab
chemical_list: D018927:Anti-Asthmatic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab